DK2007416T3

DK2007416T3 - PARATYROIDEAHORMON (PTH) TO USE IN THE TREATMENT OF ICE CREAM

PARATYROIDEAHORMON (PTH) TO USE IN THE TREATMENT OF ICE CREAM Download PDF

Info

Publication number: DK2007416T3
Authority: DK; Denmark
Prior art keywords: pth; cells; pharmaceutical composition; fragments; csf
Prior art date: 2006-04-19

Application number

DK07724213.9T

Other languages

Danish (da)

English (en)

Inventor

Wolfgang M Franz

Original Assignee

Univ Muenchen Ludwig Maximilians

Priority date

2006-04-19

Filing date

2007-04-12

Publication date

2017-12-11

2007-04-12 Application filed by Univ Muenchen Ludwig Maximilians filed Critical Univ Muenchen Ludwig Maximilians

2017-12-11 Application granted granted Critical

2017-12-11 Publication of DK2007416T3 publication Critical patent/DK2007416T3/en

Links

238000011282 treatment Methods 0.000 title claims description 90
108090000445 Parathyroid hormone Proteins 0.000 claims description 324
239000000199 parathyroid hormone Substances 0.000 claims description 324
102000003982 Parathyroid hormone Human genes 0.000 claims description 323
229960001319 parathyroid hormone Drugs 0.000 claims description 287
210000004027 cell Anatomy 0.000 claims description 133
210000000130 stem cell Anatomy 0.000 claims description 125
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 95
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 78
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 78
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 78
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 78
208000028867 ischemia Diseases 0.000 claims description 66
239000008194 pharmaceutical composition Substances 0.000 claims description 66
239000012634 fragment Substances 0.000 claims description 59
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 56
208000010125 myocardial infarction Diseases 0.000 claims description 56
108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims description 45
238000000034 method Methods 0.000 claims description 37
OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims description 33
150000001413 amino acids Chemical class 0.000 claims description 27
239000005557 antagonist Substances 0.000 claims description 22
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 21
208000031225 myocardial ischemia Diseases 0.000 claims description 18
230000000302 ischemic effect Effects 0.000 claims description 17
238000001356 surgical procedure Methods 0.000 claims description 17
230000003511 endothelial effect Effects 0.000 claims description 12
JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 claims description 11
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims description 11
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims description 11
108010054812 diprotin A Proteins 0.000 claims description 11
230000017531 blood circulation Effects 0.000 claims description 8
208000029078 coronary artery disease Diseases 0.000 claims description 8
208000014674 injury Diseases 0.000 claims description 7
238000013152 interventional procedure Methods 0.000 claims description 7
230000002093 peripheral effect Effects 0.000 claims description 7
230000008733 trauma Effects 0.000 claims description 7
208000005189 Embolism Diseases 0.000 claims description 6
SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims description 5
229960001254 vildagliptin Drugs 0.000 claims description 5
206010002388 Angina unstable Diseases 0.000 claims description 4
208000007718 Stable Angina Diseases 0.000 claims description 4
208000007814 Unstable Angina Diseases 0.000 claims description 4
201000004332 intermediate coronary syndrome Diseases 0.000 claims description 4
206010019280 Heart failures Diseases 0.000 claims description 3
108010073509 parathyroid hormone (1-31) Proteins 0.000 claims description 3
230000002537 thrombolytic effect Effects 0.000 claims description 3
206010020772 Hypertension Diseases 0.000 claims description 2
102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 2
125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 2
238000002399 angioplasty Methods 0.000 claims description 2
230000001640 apoptogenic effect Effects 0.000 claims description 2
238000005259 measurement Methods 0.000 claims description 2
108700000288 parathyroid hormone (1-28) Proteins 0.000 claims description 2
108010073230 parathyroid hormone (1-38) Proteins 0.000 claims description 2
230000007115 recruitment Effects 0.000 claims description 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 4
101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 claims 1
102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 1
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 88
210000001185 bone marrow Anatomy 0.000 description 66
230000000694 effects Effects 0.000 description 58
241001465754 Metazoa Species 0.000 description 56
241000699670 Mus sp. Species 0.000 description 53
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 53
239000011780 sodium chloride Substances 0.000 description 53
210000001519 tissue Anatomy 0.000 description 50
235000001014 amino acid Nutrition 0.000 description 43
102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 40
150000007523 nucleic acids Chemical class 0.000 description 36
101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 34
210000002216 heart Anatomy 0.000 description 34
206010061216 Infarction Diseases 0.000 description 33
230000014509 gene expression Effects 0.000 description 33
239000000203 mixture Substances 0.000 description 31
108090000765 processed proteins & peptides Proteins 0.000 description 30
125000003275 alpha amino acid group Chemical group 0.000 description 29
108090000623 proteins and genes Proteins 0.000 description 28
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 27
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 27
230000007574 infarction Effects 0.000 description 27
210000005259 peripheral blood Anatomy 0.000 description 26
239000011886 peripheral blood Substances 0.000 description 26
102000004169 proteins and genes Human genes 0.000 description 26
235000018102 proteins Nutrition 0.000 description 25
230000002829 reductive effect Effects 0.000 description 25
108020004414 DNA Proteins 0.000 description 24
102000039446 nucleic acids Human genes 0.000 description 24
108020004707 nucleic acids Proteins 0.000 description 24
102000043299 Parathyroid hormone-related Human genes 0.000 description 22
230000002107 myocardial effect Effects 0.000 description 22
150000001875 compounds Chemical class 0.000 description 21
101710123753 Parathyroid hormone-related protein Proteins 0.000 description 20
239000003112 inhibitor Substances 0.000 description 20
238000006467 substitution reaction Methods 0.000 description 20
230000001976 improved effect Effects 0.000 description 19
210000000056 organ Anatomy 0.000 description 19
230000004083 survival effect Effects 0.000 description 19
206010063560 Excessive granulation tissue Diseases 0.000 description 18
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 18
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 18
210000004413 cardiac myocyte Anatomy 0.000 description 18
210000001126 granulation tissue Anatomy 0.000 description 18
102000004196 processed proteins & peptides Human genes 0.000 description 18
239000000758 substrate Substances 0.000 description 18
230000006870 function Effects 0.000 description 17
210000003958 hematopoietic stem cell Anatomy 0.000 description 17
229920001184 polypeptide Polymers 0.000 description 17
241000282414 Homo sapiens Species 0.000 description 16
230000000638 stimulation Effects 0.000 description 16
102000004127 Cytokines Human genes 0.000 description 15
108090000695 Cytokines Proteins 0.000 description 15
206010029113 Neovascularisation Diseases 0.000 description 15
230000007423 decrease Effects 0.000 description 15
210000004165 myocardium Anatomy 0.000 description 15
102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 14
108010016626 Dipeptides Proteins 0.000 description 14
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 14
102400000322 Glucagon-like peptide 1 Human genes 0.000 description 14
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 14
208000006011 Stroke Diseases 0.000 description 14
230000000747 cardiac effect Effects 0.000 description 14
230000004217 heart function Effects 0.000 description 14
230000001404 mediated effect Effects 0.000 description 14
230000015556 catabolic process Effects 0.000 description 13
238000003776 cleavage reaction Methods 0.000 description 13
238000006731 degradation reaction Methods 0.000 description 13
238000009396 hybridization Methods 0.000 description 13
230000007246 mechanism Effects 0.000 description 13
230000007017 scission Effects 0.000 description 13
210000002966 serum Anatomy 0.000 description 13
101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 12
102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 12
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 12
238000004458 analytical method Methods 0.000 description 12
230000009286 beneficial effect Effects 0.000 description 12
239000008280 blood Substances 0.000 description 12
230000003394 haemopoietic effect Effects 0.000 description 12
238000001727 in vivo Methods 0.000 description 12
230000005012 migration Effects 0.000 description 12
238000013508 migration Methods 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
108091093037 Peptide nucleic acid Proteins 0.000 description 11
210000004369 blood Anatomy 0.000 description 11
239000011575 calcium Substances 0.000 description 11
229910052791 calcium Inorganic materials 0.000 description 11
230000000295 complement effect Effects 0.000 description 11
230000006872 improvement Effects 0.000 description 11
239000000126 substance Substances 0.000 description 11
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 10
241000700159 Rattus Species 0.000 description 10
230000003247 decreasing effect Effects 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
230000001483 mobilizing effect Effects 0.000 description 10
210000001616 monocyte Anatomy 0.000 description 10
238000010172 mouse model Methods 0.000 description 10
210000000963 osteoblast Anatomy 0.000 description 10
230000009467 reduction Effects 0.000 description 10
230000008439 repair process Effects 0.000 description 10
239000000243 solution Substances 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 9
102000006461 Parathyroid Hormone Receptors Human genes 0.000 description 9
108010058828 Parathyroid Hormone Receptors Proteins 0.000 description 9
125000000539 amino acid group Chemical group 0.000 description 9
230000006907 apoptotic process Effects 0.000 description 9
210000002798 bone marrow cell Anatomy 0.000 description 9
125000003729 nucleotide group Chemical group 0.000 description 9
238000002054 transplantation Methods 0.000 description 9
108091028043 Nucleic acid sequence Proteins 0.000 description 8
230000004913 activation Effects 0.000 description 8
230000037396 body weight Effects 0.000 description 8
210000000988 bone and bone Anatomy 0.000 description 8
230000007547 defect Effects 0.000 description 8
108020004999 messenger RNA Proteins 0.000 description 8
230000010016 myocardial function Effects 0.000 description 8
239000002773 nucleotide Substances 0.000 description 8
230000002265 prevention Effects 0.000 description 8
230000002861 ventricular Effects 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 7
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 7
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 7
230000001419 dependent effect Effects 0.000 description 7
239000003814 drug Substances 0.000 description 7
210000002889 endothelial cell Anatomy 0.000 description 7
229940088598 enzyme Drugs 0.000 description 7
238000009472 formulation Methods 0.000 description 7
239000003102 growth factor Substances 0.000 description 7
238000001802 infusion Methods 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
108091033319 polynucleotide Proteins 0.000 description 7
102000040430 polynucleotide Human genes 0.000 description 7
230000011664 signaling Effects 0.000 description 7
238000010186 staining Methods 0.000 description 7
206010002329 Aneurysm Diseases 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 6
102000038455 IGF Type 1 Receptor Human genes 0.000 description 6
108010031794 IGF Type 1 Receptor Proteins 0.000 description 6
102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 6
108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 6
108091007960 PI3Ks Proteins 0.000 description 6
239000002253 acid Substances 0.000 description 6
150000007513 acids Chemical class 0.000 description 6
210000001367 artery Anatomy 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
238000000684 flow cytometry Methods 0.000 description 6
238000005755 formation reaction Methods 0.000 description 6
229940088597 hormone Drugs 0.000 description 6
239000005556 hormone Substances 0.000 description 6
239000002157 polynucleotide Substances 0.000 description 6
230000035755 proliferation Effects 0.000 description 6
101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 5
230000001154 acute effect Effects 0.000 description 5
230000002491 angiogenic effect Effects 0.000 description 5
238000013459 approach Methods 0.000 description 5
210000002565 arteriole Anatomy 0.000 description 5
-1 azide anhydride Chemical class 0.000 description 5
230000000903 blocking effect Effects 0.000 description 5
238000004422 calculation algorithm Methods 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
229940079593 drug Drugs 0.000 description 5
230000004064 dysfunction Effects 0.000 description 5
210000003714 granulocyte Anatomy 0.000 description 5
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
210000005087 mononuclear cell Anatomy 0.000 description 5
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
AUUIARVPJHGTSA-UHFFFAOYSA-N 3-(aminomethyl)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(CN)=CC2=C1 AUUIARVPJHGTSA-UHFFFAOYSA-N 0.000 description 4
201000001320 Atherosclerosis Diseases 0.000 description 4
102000000905 Cadherin Human genes 0.000 description 4
108050007957 Cadherin Proteins 0.000 description 4
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 4
102000000646 Interleukin-3 Human genes 0.000 description 4
108010002386 Interleukin-3 Proteins 0.000 description 4
102000004889 Interleukin-6 Human genes 0.000 description 4
108090001005 Interleukin-6 Proteins 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
108050000637 N-cadherin Proteins 0.000 description 4
206010028851 Necrosis Diseases 0.000 description 4
108700020797 Parathyroid Hormone-Related Proteins 0.000 description 4
108010004729 Phycoerythrin Proteins 0.000 description 4
238000012300 Sequence Analysis Methods 0.000 description 4
239000003708 ampul Substances 0.000 description 4
230000033115 angiogenesis Effects 0.000 description 4
230000027746 artery morphogenesis Effects 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
230000012292 cell migration Effects 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
206010008118 cerebral infarction Diseases 0.000 description 4
230000008859 change Effects 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
230000034994 death Effects 0.000 description 4
231100000517 death Toxicity 0.000 description 4
238000001514 detection method Methods 0.000 description 4
230000003205 diastolic effect Effects 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
230000012010 growth Effects 0.000 description 4
230000036541 health Effects 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
239000001257 hydrogen Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
229940076264 interleukin-3 Drugs 0.000 description 4
229940100601 interleukin-6 Drugs 0.000 description 4
230000036244 malformation Effects 0.000 description 4
230000017074 necrotic cell death Effects 0.000 description 4
230000002018 overexpression Effects 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
230000037361 pathway Effects 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
230000026731 phosphorylation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
230000008569 process Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
230000001172 regenerating effect Effects 0.000 description 4
238000007634 remodeling Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
230000028327 secretion Effects 0.000 description 4
230000035939 shock Effects 0.000 description 4
229960004034 sitagliptin Drugs 0.000 description 4
MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 4
238000007619 statistical method Methods 0.000 description 4
238000009168 stem cell therapy Methods 0.000 description 4
238000011476 stem cell transplantation Methods 0.000 description 4
238000009580 stem-cell therapy Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
230000002792 vascular Effects 0.000 description 4
230000024883 vasodilation Effects 0.000 description 4
201000006474 Brain Ischemia Diseases 0.000 description 3
238000011740 C57BL/6 mouse Methods 0.000 description 3
206010007572 Cardiac hypertrophy Diseases 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
206010008120 Cerebral ischaemia Diseases 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
102100031939 Erythropoietin Human genes 0.000 description 3
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 3
101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 description 3
101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 3
101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 3
208000037147 Hypercalcaemia Diseases 0.000 description 3
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 3
108700003486 Jagged-1 Proteins 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
102100032702 Protein jagged-1 Human genes 0.000 description 3
108700037966 Protein jagged-1 Proteins 0.000 description 3
GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 3
241000282887 Suidae Species 0.000 description 3
RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 3
206010047141 Vasodilatation Diseases 0.000 description 3
241000251539 Vertebrata <Metazoa> Species 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
230000009471 action Effects 0.000 description 3
206010000891 acute myocardial infarction Diseases 0.000 description 3
238000007792 addition Methods 0.000 description 3
239000002870 angiogenesis inducing agent Substances 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
210000000601 blood cell Anatomy 0.000 description 3
230000036770 blood supply Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
206010007625 cardiogenic shock Diseases 0.000 description 3
230000003293 cardioprotective effect Effects 0.000 description 3
210000001715 carotid artery Anatomy 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
210000004351 coronary vessel Anatomy 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000002950 deficient Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
230000002489 hematologic effect Effects 0.000 description 3
230000000004 hemodynamic effect Effects 0.000 description 3
102000058004 human PTH Human genes 0.000 description 3
230000000148 hypercalcaemia Effects 0.000 description 3
208000030915 hypercalcemia disease Diseases 0.000 description 3
238000011532 immunohistochemical staining Methods 0.000 description 3
238000012744 immunostaining Methods 0.000 description 3
230000001771 impaired effect Effects 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000008595 infiltration Effects 0.000 description 3
238000001764 infiltration Methods 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
210000005240 left ventricle Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
230000035772 mutation Effects 0.000 description 3
208000002089 myocardial stunning Diseases 0.000 description 3
230000001582 osteoblastic effect Effects 0.000 description 3
230000000849 parathyroid Effects 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
230000001766 physiological effect Effects 0.000 description 3
230000008092 positive effect Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000004853 protein function Effects 0.000 description 3
230000008929 regeneration Effects 0.000 description 3
238000011069 regeneration method Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000000250 revascularization Effects 0.000 description 3
210000000329 smooth muscle myocyte Anatomy 0.000 description 3
210000000603 stem cell niche Anatomy 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
210000002536 stromal cell Anatomy 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
238000010361 transduction Methods 0.000 description 3
230000026683 transduction Effects 0.000 description 3
ZOWOHMFPXMYFKJ-WBTWNKCNSA-N (4S)-4-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]-5-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(1S)-1-carboxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)[C@@H](C)CC)C1=CN=CN1 ZOWOHMFPXMYFKJ-WBTWNKCNSA-N 0.000 description 2
UTDVHCQTKWTQEA-UHFFFAOYSA-N 1-(2-aminoacetyl)-n-(4-methyl-2-oxochromen-7-yl)pyrrolidine-2-carboxamide Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1NC(=O)C1CCCN1C(=O)CN UTDVHCQTKWTQEA-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
108091023037 Aptamer Proteins 0.000 description 2
NABSCJGZKWSNHX-RCWTZXSCSA-N Arg-Arg-Thr Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NABSCJGZKWSNHX-RCWTZXSCSA-N 0.000 description 2
ZBYLEBZCVKLPCY-FXQIFTODSA-N Asp-Ser-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ZBYLEBZCVKLPCY-FXQIFTODSA-N 0.000 description 2
KGHLGJAXYSVNJP-WHFBIAKZSA-N Asp-Ser-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O KGHLGJAXYSVNJP-WHFBIAKZSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 2
108010061299 CXCR4 Receptors Proteins 0.000 description 2
102000012000 CXCR4 Receptors Human genes 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
208000001778 Coronary Occlusion Diseases 0.000 description 2
206010011086 Coronary artery occlusion Diseases 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
108010029961 Filgrastim Proteins 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
MTAOBYXRYJZRGQ-WDSKDSINSA-N Glu-Gly-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MTAOBYXRYJZRGQ-WDSKDSINSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
NTBOEZICHOSJEE-YUMQZZPRSA-N Gly-Lys-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NTBOEZICHOSJEE-YUMQZZPRSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
102100021866 Hepatocyte growth factor Human genes 0.000 description 2
101001074954 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 5-phosphatase A Proteins 0.000 description 2
102000003746 Insulin Receptor Human genes 0.000 description 2
108010001127 Insulin Receptor Proteins 0.000 description 2
102100025087 Insulin receptor substrate 1 Human genes 0.000 description 2
101710201824 Insulin receptor substrate 1 Proteins 0.000 description 2
102100025092 Insulin receptor substrate 2 Human genes 0.000 description 2
101710201820 Insulin receptor substrate 2 Proteins 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
108010062867 Lenograstim Proteins 0.000 description 2
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
208000034827 Neointima Diseases 0.000 description 2
102000005650 Notch Receptors Human genes 0.000 description 2
108010070047 Notch Receptors Proteins 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
BIYWZVCPZIFGPY-QWRGUYRKSA-N Phe-Gly-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CO)C(O)=O BIYWZVCPZIFGPY-QWRGUYRKSA-N 0.000 description 2
102100035985 Phosphatidylinositol 4,5-bisphosphate 5-phosphatase A Human genes 0.000 description 2
239000004952 Polyamide Substances 0.000 description 2
ZKQOUHVVXABNDG-IUCAKERBSA-N Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 ZKQOUHVVXABNDG-IUCAKERBSA-N 0.000 description 2
WWXNZNWZNZPDIF-SRVKXCTJSA-N Pro-Val-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 WWXNZNWZNZPDIF-SRVKXCTJSA-N 0.000 description 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
101001135767 Rattus norvegicus Parathyroid hormone Proteins 0.000 description 2
JLKWJWPDXPKKHI-FXQIFTODSA-N Ser-Pro-Asn Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CC(=O)N)C(=O)O JLKWJWPDXPKKHI-FXQIFTODSA-N 0.000 description 2
108020004459 Small interfering RNA Proteins 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
MXDOAJQRJBMGMO-FJXKBIBVSA-N Thr-Pro-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O MXDOAJQRJBMGMO-FJXKBIBVSA-N 0.000 description 2
AHERARIZBPOMNU-KATARQTJSA-N Thr-Ser-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O AHERARIZBPOMNU-KATARQTJSA-N 0.000 description 2
XWYUBUYQMOUFRQ-IFFSRLJSSA-N Val-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N)O XWYUBUYQMOUFRQ-IFFSRLJSSA-N 0.000 description 2
YQYFYUSYEDNLSD-YEPSODPASA-N Val-Thr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O YQYFYUSYEDNLSD-YEPSODPASA-N 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000003321 amplification Effects 0.000 description 2
210000000648 angioblast Anatomy 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
238000001210 attenuated total reflectance infrared spectroscopy Methods 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
229920001222 biopolymer Polymers 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
230000003491 cAMP production Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
230000002281 colonystimulating effect Effects 0.000 description 2
238000004590 computer program Methods 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
238000000432 density-gradient centrifugation Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000012137 double-staining Methods 0.000 description 2
230000004761 fibrosis Effects 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
108010037850 glycylvaline Proteins 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
230000011132 hemopoiesis Effects 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
230000013632 homeostatic process Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
208000023589 ischemic disease Diseases 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000008101 lactose Substances 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
229960004194 lidocaine Drugs 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000003589 local anesthetic agent Substances 0.000 description 2
230000007774 longterm Effects 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
230000018901 negative regulation of programmed cell death Effects 0.000 description 2
230000008692 neointimal formation Effects 0.000 description 2
210000000885 nephron Anatomy 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
238000007899 nucleic acid hybridization Methods 0.000 description 2
230000004768 organ dysfunction Effects 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
210000002990 parathyroid gland Anatomy 0.000 description 2
108010054971 parathyroid hormone-related protein (1-34) Proteins 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229920002647 polyamide Polymers 0.000 description 2
230000001323 posttranslational effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
108010090894 prolylleucine Proteins 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000031477 regulation of parathyroid hormone secretion Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
210000001646 side-population cell Anatomy 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
210000002027 skeletal muscle Anatomy 0.000 description 2
239000002904 solvent Substances 0.000 description 2
241000894007 species Species 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008227 sterile water for injection Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
108010080629 tryptophan-leucine Proteins 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
210000005166 vasculature Anatomy 0.000 description 2
230000001196 vasorelaxation Effects 0.000 description 2
FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
RRBGTUQJDFBWNN-MUGJNUQGSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2,6-diaminohexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O RRBGTUQJDFBWNN-MUGJNUQGSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
HWTAKVLMACWHLD-UHFFFAOYSA-N 2-(9h-carbazol-1-yl)ethanamine Chemical compound C12=CC=CC=C2NC2=C1C=CC=C2CCN HWTAKVLMACWHLD-UHFFFAOYSA-N 0.000 description 1
MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical class OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
CZVCGJBESNRLEQ-UHFFFAOYSA-N 7h-purine;pyrimidine Chemical compound C1=CN=CN=C1.C1=NC=C2NC=NC2=N1 CZVCGJBESNRLEQ-UHFFFAOYSA-N 0.000 description 1
230000005730 ADP ribosylation Effects 0.000 description 1
235000007173 Abies balsamea Nutrition 0.000 description 1
208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
YXXPVUOMPSZURS-ZLIFDBKOSA-N Ala-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](C)N)=CNC2=C1 YXXPVUOMPSZURS-ZLIFDBKOSA-N 0.000 description 1
REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
244000105975 Antidesma platyphyllum Species 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
OTOXOKCIIQLMFH-KZVJFYERSA-N Arg-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N OTOXOKCIIQLMFH-KZVJFYERSA-N 0.000 description 1
CVXXSWQORBZAAA-SRVKXCTJSA-N Arg-Lys-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N CVXXSWQORBZAAA-SRVKXCTJSA-N 0.000 description 1
MNBHKGYCLBUIBC-UFYCRDLUSA-N Arg-Phe-Phe Chemical compound C([C@H](NC(=O)[C@H](CCCNC(N)=N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MNBHKGYCLBUIBC-UFYCRDLUSA-N 0.000 description 1
KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 1
208000022211 Arteriovenous Malformations Diseases 0.000 description 1
GMRGSBAMMMVDGG-GUBZILKMSA-N Asn-Arg-Arg Chemical compound C(C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)CN=C(N)N GMRGSBAMMMVDGG-GUBZILKMSA-N 0.000 description 1
QJMCHPGWFZZRID-BQBZGAKWSA-N Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O QJMCHPGWFZZRID-BQBZGAKWSA-N 0.000 description 1
CKAJHWFHHFSCDT-WHFBIAKZSA-N Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O CKAJHWFHHFSCDT-WHFBIAKZSA-N 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
208000027580 BK-virus nephropathy Diseases 0.000 description 1
239000004857 Balsam Substances 0.000 description 1
102000015735 Beta-catenin Human genes 0.000 description 1
108060000903 Beta-catenin Proteins 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
235000021318 Calcifediol Nutrition 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
206010008089 Cerebral artery occlusion Diseases 0.000 description 1
108010008951 Chemokine CXCL12 Proteins 0.000 description 1
241001300671 Cnidoscolus Species 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
108010014172 Factor V Proteins 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
PJBVXVBTTFZPHJ-GUBZILKMSA-N Glu-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N PJBVXVBTTFZPHJ-GUBZILKMSA-N 0.000 description 1
BBBXWRGITSUJPB-YUMQZZPRSA-N Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O BBBXWRGITSUJPB-YUMQZZPRSA-N 0.000 description 1
HRBYTAIBKPNZKQ-AVGNSLFASA-N Glu-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O HRBYTAIBKPNZKQ-AVGNSLFASA-N 0.000 description 1
JVYNYWXHZWVJEF-NUMRIWBASA-N Glu-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O JVYNYWXHZWVJEF-NUMRIWBASA-N 0.000 description 1
XUORRGAFUQIMLC-STQMWFEESA-N Gly-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN)O XUORRGAFUQIMLC-STQMWFEESA-N 0.000 description 1
LLXVQPKEQQCISF-YUMQZZPRSA-N Gly-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN LLXVQPKEQQCISF-YUMQZZPRSA-N 0.000 description 1
LLZXNUUIBOALNY-QWRGUYRKSA-N Gly-Leu-Lys Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN LLZXNUUIBOALNY-QWRGUYRKSA-N 0.000 description 1
WDEHMRNSGHVNOH-VHSXEESVSA-N Gly-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)CN)C(=O)O WDEHMRNSGHVNOH-VHSXEESVSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
BDHUXUFYNUOUIT-SRVKXCTJSA-N His-Asp-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BDHUXUFYNUOUIT-SRVKXCTJSA-N 0.000 description 1
LVXFNTIIGOQBMD-SRVKXCTJSA-N His-Leu-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O LVXFNTIIGOQBMD-SRVKXCTJSA-N 0.000 description 1
102100021455 Histone deacetylase 3 Human genes 0.000 description 1
102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 description 1
101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
101000899282 Homo sapiens Histone deacetylase 3 Proteins 0.000 description 1
101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
101001054645 Homo sapiens Integrator complex subunit 13 Proteins 0.000 description 1
101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
201000002980 Hyperparathyroidism Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
244000018716 Impatiens biflora Species 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
102100027019 Integrator complex subunit 13 Human genes 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
101150113031 Jag1 gene Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
206010024119 Left ventricular failure Diseases 0.000 description 1
PJWOOBTYQNNRBF-BZSNNMDCSA-N Leu-Phe-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)O)N PJWOOBTYQNNRBF-BZSNNMDCSA-N 0.000 description 1
IZPVWNSAVUQBGP-CIUDSAMLSA-N Leu-Ser-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IZPVWNSAVUQBGP-CIUDSAMLSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
CLBGMWIYPYAZPR-AVGNSLFASA-N Lys-Arg-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O CLBGMWIYPYAZPR-AVGNSLFASA-N 0.000 description 1
UQRZFMQQXXJTTF-AVGNSLFASA-N Lys-Lys-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O UQRZFMQQXXJTTF-AVGNSLFASA-N 0.000 description 1
YUAXTFMFMOIMAM-QWRGUYRKSA-N Lys-Lys-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O YUAXTFMFMOIMAM-QWRGUYRKSA-N 0.000 description 1
PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 1
108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
241000315922 Mecysmauchenius fernandez Species 0.000 description 1
241001608711 Melo Species 0.000 description 1
102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
241000204795 Muraena helena Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101000746384 Mus musculus Granulocyte colony-stimulating factor Proteins 0.000 description 1
101000716728 Mus musculus Kit ligand Proteins 0.000 description 1
WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 1
108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000906034 Orthops Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
102100036893 Parathyroid hormone Human genes 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
108700020962 Peroxidase Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
102100035194 Placenta growth factor Human genes 0.000 description 1
206010065381 Polyomavirus-associated nephropathy Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000288906 Primates Species 0.000 description 1
SWXSLPHTJVAWDF-VEVYYDQMSA-N Pro-Asn-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWXSLPHTJVAWDF-VEVYYDQMSA-N 0.000 description 1
241000754872 Progne elegans Species 0.000 description 1
241000778500 Promethichthys prometheus Species 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
238000010240 RT-PCR analysis Methods 0.000 description 1
206010063897 Renal ischaemia Diseases 0.000 description 1
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
241000607686 Salmonella enterica subsp. enterica serovar Thompson Species 0.000 description 1
VBKBDLMWICBSCY-IMJSIDKUSA-N Ser-Asp Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O VBKBDLMWICBSCY-IMJSIDKUSA-N 0.000 description 1
LAFKUZYWNCHOHT-WHFBIAKZSA-N Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O LAFKUZYWNCHOHT-WHFBIAKZSA-N 0.000 description 1
UICKAKRRRBTILH-GUBZILKMSA-N Ser-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N UICKAKRRRBTILH-GUBZILKMSA-N 0.000 description 1
OHKFXGKHSJKKAL-NRPADANISA-N Ser-Glu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OHKFXGKHSJKKAL-NRPADANISA-N 0.000 description 1
ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 1
PTWIYDNFWPXQSD-GARJFASQSA-N Ser-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N)C(=O)O PTWIYDNFWPXQSD-GARJFASQSA-N 0.000 description 1
WBAXJMCUFIXCNI-WDSKDSINSA-N Ser-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WBAXJMCUFIXCNI-WDSKDSINSA-N 0.000 description 1
FKYWFUYPVKLJLP-DCAQKATOSA-N Ser-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FKYWFUYPVKLJLP-DCAQKATOSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
208000036982 Spinal cord ischaemia Diseases 0.000 description 1
102100030416 Stromelysin-1 Human genes 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
108010049264 Teriparatide Proteins 0.000 description 1
IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
VPZKQTYZIVOJDV-LMVFSUKVSA-N Thr-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(O)=O VPZKQTYZIVOJDV-LMVFSUKVSA-N 0.000 description 1
FQPQPTHMHZKGFM-XQXXSGGOSA-N Thr-Ala-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O FQPQPTHMHZKGFM-XQXXSGGOSA-N 0.000 description 1
BSNZTJXVDOINSR-JXUBOQSCSA-N Thr-Ala-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BSNZTJXVDOINSR-JXUBOQSCSA-N 0.000 description 1
CEXFELBFVHLYDZ-XGEHTFHBSA-N Thr-Arg-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CEXFELBFVHLYDZ-XGEHTFHBSA-N 0.000 description 1
BDGBHYCAZJPLHX-HJGDQZAQSA-N Thr-Lys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BDGBHYCAZJPLHX-HJGDQZAQSA-N 0.000 description 1
108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
108020004566 Transfer RNA Proteins 0.000 description 1
208000032109 Transient ischaemic attack Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
LYMVXFSTACVOLP-ZFWWWQNUSA-N Trp-Leu Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C([O-])=O)=CNC2=C1 LYMVXFSTACVOLP-ZFWWWQNUSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
241000063673 Urena Species 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
VIKZGAUAKQZDOF-NRPADANISA-N Val-Ser-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O VIKZGAUAKQZDOF-NRPADANISA-N 0.000 description 1
GVRKWABULJAONN-VQVTYTSYSA-N Val-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVRKWABULJAONN-VQVTYTSYSA-N 0.000 description 1
208000033774 Ventricular Remodeling Diseases 0.000 description 1
102000013814 Wnt Human genes 0.000 description 1
108050003627 Wnt Proteins 0.000 description 1
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
DDMXPIDWXIHIDX-UHFFFAOYSA-N [C].N1C=NC=C1 Chemical compound [C].N1C=NC=C1 DDMXPIDWXIHIDX-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
206010000496 acne Diseases 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
102000019997 adhesion receptor Human genes 0.000 description 1
108010013985 adhesion receptor Proteins 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
238000012867 alanine scanning Methods 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
230000008850 allosteric inhibition Effects 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000002424 anti-apoptotic effect Effects 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
108010018691 arginyl-threonyl-arginine Proteins 0.000 description 1
108010068380 arginylarginine Proteins 0.000 description 1
230000010516 arginylation Effects 0.000 description 1
230000001623 arteriogenic effect Effects 0.000 description 1
230000005744 arteriovenous malformation Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
108010038633 aspartylglutamate Proteins 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
238000002869 basic local alignment search tool Methods 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003851 biochemical process Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 1
229960004361 calcifediol Drugs 0.000 description 1
229960005084 calcitriol Drugs 0.000 description 1
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
235000020964 calcitriol Nutrition 0.000 description 1
239000011612 calcitriol Substances 0.000 description 1
230000009460 calcium influx Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000001269 cardiogenic effect Effects 0.000 description 1
230000008209 cardiovascular development Effects 0.000 description 1
230000009084 cardiovascular function Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000030833 cell death Effects 0.000 description 1
238000011072 cell harvest Methods 0.000 description 1
230000006041 cell recruitment Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
230000002057 chronotropic effect Effects 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000000512 collagen gel Substances 0.000 description 1
230000006467 collateral growth Effects 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000008828 contractile function Effects 0.000 description 1
238000002586 coronary angiography Methods 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
238000011262 co‐therapy Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000010339 dilation Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
229960004177 filgrastim Drugs 0.000 description 1
238000011049 filling Methods 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
238000007421 fluorometric assay Methods 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
238000010230 functional analysis Methods 0.000 description 1
230000006251 gamma-carboxylation Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000006377 glucose transport Effects 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
108010015792 glycyllysine Proteins 0.000 description 1
210000004349 growth plate Anatomy 0.000 description 1
235000009424 haa Nutrition 0.000 description 1
150000003278 haem Chemical group 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
210000000777 hematopoietic system Anatomy 0.000 description 1
108010028295 histidylhistidine Proteins 0.000 description 1
102000044493 human CDCA4 Human genes 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
238000002991 immunohistochemical analysis Methods 0.000 description 1
230000036046 immunoreaction Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
230000004171 ischemic cascade Effects 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
229960002618 lenograstim Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000002865 local sequence alignment Methods 0.000 description 1
208000012866 low blood pressure Diseases 0.000 description 1
108010054155 lysyllysine Proteins 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
201000007309 middle cerebral artery infarction Diseases 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000002894 multi-fate stem cell Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003680 myocardial damage Effects 0.000 description 1
210000000107 myocyte Anatomy 0.000 description 1
230000007498 myristoylation Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229940029345 neupogen Drugs 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
230000002188 osteogenic effect Effects 0.000 description 1
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000006320 pegylation Effects 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
229910001392 phosphorus oxide Inorganic materials 0.000 description 1
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical class [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 1
229960002169 plerixafor Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000036316 preload Effects 0.000 description 1
230000013823 prenylation Effects 0.000 description 1
238000004321 preservation Methods 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000001023 pro-angiogenic effect Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
108010029020 prolylglycine Proteins 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
229940043131 pyroglutamate Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000006340 racemization Effects 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
239000003642 reactive oxygen metabolite Substances 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
230000002629 repopulating effect Effects 0.000 description 1
208000032253 retinal ischemia Diseases 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
229940055619 selenocysteine Drugs 0.000 description 1
235000016491 selenocysteine Nutrition 0.000 description 1
108010026333 seryl-proline Proteins 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
108010005652 splenotritin Proteins 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
210000003537 structural cell Anatomy 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000019635 sulfation Effects 0.000 description 1
238000005670 sulfation reaction Methods 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960005460 teriparatide Drugs 0.000 description 1
229960003279 thiopental Drugs 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
210000002303 tibia Anatomy 0.000 description 1
230000009092 tissue dysfunction Effects 0.000 description 1
238000012549 training Methods 0.000 description 1
201000010875 transient cerebral ischemia Diseases 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000013042 tunel staining Methods 0.000 description 1
230000034512 ubiquitination Effects 0.000 description 1
238000010798 ubiquitination Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
238000011870 unpaired t-test Methods 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1
239000008096 xylene Substances 0.000 description 1